Mifepristone Repurposing in Treatment of High-Grade Gliomas
Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 month...
Main Authors: | Monserrat Llaguno-Munive, Maria Ines Vazquez-Lopez, Rafael Jurado, Patricia Garcia-Lopez |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.606907/full |
Similar Items
-
Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
by: Monserrat Llaguno-Munive, et al.
Published: (2020-10-01) -
Disulfiram in glioma: Literature review of drug repurposing
by: Shiyu Zhong, et al.
Published: (2022-08-01) -
Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery—A Comprehensive Review of the Literature
by: Safwan Alomari, et al.
Published: (2021-12-01) -
Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomes Co-Loaded with Cisplatin and Mifepristone
by: Karen Ocaña-Arakachi, et al.
Published: (2023-09-01) -
Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma
by: Monserrat Llaguno-Munive, et al.
Published: (2018-12-01)